Weiner David A, Murphy Jordan P, Gwam Chukwuweike, Loughran Galvin J, Vulpis Christian, Milzman David P, Wisbeck Jacob M
Department of Orthopedic Surgery, MedStar Union Memorial Hospital, Baltimore, MD, USA.
Georgetown University School of Medicine, Washington, DC, USA.
Eur J Orthop Surg Traumatol. 2019 Aug;29(6):1319-1323. doi: 10.1007/s00590-019-02428-0. Epub 2019 Apr 8.
Opioids are commonly used for post-operative pain control. It is known that diabetic patients with ankle fractures will experience prolonged healing, higher risk of hardware failure, and an increased risk of infection. However, the opioid requirements amongst this patient cohort have not been previously evaluated. Thus, the purpose of this study is to retrospectively compare opioid utilization amongst ankle fracture patients with and without diabetes mellitus (DM).
An IRB approval was obtained for the retrospective review of patients who presented with an ankle fracture and underwent surgery between November 2013 and January 2017. A total of 180 patients (144 without DM, 36 with DM) with a mean age of 50 years (± 18 years) were included. Opioid consumption was quantified utilizing a morphine-milliequivalent conversion algorithm. A repeated measures ANOVA was conducted to compare opioid consumption. A two-tailed p value of 0.05 was set as the threshold for statistical significance.
Repeated measures ANOVA revealed a statistically significant decrease in total opioid consumption during the 4-month duration (p < 0.001). The model demonstrated a mean difference in opioid consumption of - 214.3 morphine meq between the patients without and with DM (p = 0.022). Post hoc pair-wise comparison revealed less opioid consumption amongst non-diabetic patients at 2 (- 418.5 Meq; p = 0.009), 3 months (- 355.6 Meq; p = 0.021), and 4 months (- 152.6 Meq; p = 0.006) after surgery.
Our study revealed increased opioid consumption amongst diabetic patients who are treated surgically for ankle fractures. With increasing efforts aimed at reducing opioid administration, orthopaedic surgeons should be aware of higher opioid consumption amongst this patient cohort. Further studies are needed to verify the results of this study.
阿片类药物常用于术后疼痛控制。众所周知,患有踝关节骨折的糖尿病患者愈合时间会延长,内固定失败风险更高,感染风险也会增加。然而,此前尚未评估过该患者群体对阿片类药物的需求量。因此,本研究的目的是回顾性比较患有和未患有糖尿病(DM)的踝关节骨折患者的阿片类药物使用情况。
本研究获得了机构审查委员会(IRB)的批准,对2013年11月至2017年1月期间因踝关节骨折而接受手术的患者进行回顾性分析。共纳入180例患者(144例无糖尿病,36例有糖尿病),平均年龄为50岁(±18岁)。使用吗啡-毫克当量转换算法对阿片类药物的消耗量进行量化。采用重复测量方差分析来比较阿片类药物的消耗量。设定双尾p值0.05作为统计学显著性阈值。
重复测量方差分析显示,在4个月期间,阿片类药物的总消耗量有统计学显著下降(p<0.001)。该模型显示,无糖尿病和有糖尿病的患者之间阿片类药物消耗量的平均差异为-214.3吗啡毫克当量(p=0.022)。事后两两比较显示,非糖尿病患者在术后2个月(-418.5毫克当量;p=0.009)、3个月(-355.6毫克当量;p=0.021)和4个月(-152.6毫克当量;p=0.006)时的阿片类药物消耗量较少。
我们的研究表明,接受踝关节骨折手术治疗的糖尿病患者的阿片类药物消耗量增加。随着减少阿片类药物使用的努力不断加大,骨科医生应意识到该患者群体的阿片类药物消耗量较高。需要进一步的研究来验证本研究的结果。